Cat.No. : AAVH003Z
Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml
Serotype: AAV Serotype 8 Storage: -80 ℃
| Cat. No. | AAVH003Z |
| Description | AAV serotype 8 (AAV8) viral particles containing replication defective genome DNA of Hepatitis B virus (HBV) genotype C. |
| Serotype | AAV Serotype 8 |
| Product Type | AAV viral particles |
| Application | HBV-C/RD AAV (serotype 8) is a modified adeno-associated virus (AAV) vector for gene therapy that specifically targets the hepatitis B virus (HBV) for potential therapeutic intervention. AAV vectors are popular tools in gene therapy because of their ability to deliver genetic material into cells with high efficiency and minimal immune response. The following are some of the key applications and potential therapeutic uses of HBV-C/RD AAV (serotype 8): Chronic Hepatitis B treatment: This vector can be used to deliver gene editing tools such as CRISPR/Cas9 to specific liver cells infected with HBV. The goal is to excise or degrade the covalently closed circular DNA (cccDNA) of HBV, thereby reducing or eliminating viral persistence. It can also deliver small interfering RNA (siRNA) or short hairpin RNA (shRNA) constructs to inhibit HBV gene expression, significantly reducing viral replication. Liver-specific gene therapy: In addition to HBV, AAV8 (serotype 8) has a natural tropism for hepatocytes, making it a suitable candidate for the treatment of other liver-specific diseases such as inherited diseases (e.g., hemophilia) or metabolic liver diseases. Vaccine development: AAV vectors can be used to develop therapeutic vaccines designed to enhance the host immune response to HBV, resulting in sustained immunity and clearance of the virus from infected cells. Functional studies: In a research setting, this vector enables scientists to study the biology of HBV infection, hepatic gene expression, and the effects of various genetic modifications, thereby enhancing our understanding and potentially leading to therapeutic breakthroughs. |
| Applications | Cell-based HBV assays, developing HBV infection mouse models |
| Insert | Genome DNA of Hepatitis B virus (HBV) genotype C |
| Titer | Varies lot by lot, typically ≥1x10^12 GC/mL |
| Size | Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc. |
| Storage | Store at -80℃. Avoid multiple freeze/thaw cycles. |
| Shipping | Frozen on dry ice |
| Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots. | |
| Endotoxin | Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance. |
| Purity | AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE. |
| Sterility | The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth. |
| Transducibility | Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities. |
| Empty vs. Full Capsids | Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods. |
A: Please avoid unnecessary thawing and refreezing after receipt of AAV, as freeze-thaw cycles can affect virus viability. If aliquots are required, it is recommended to use PCR tubes with siliconized inner walls or special virus preservation tubes with low protein binding rates.
A: The capsid proteins of different AAV serotypes recognize different receptors on the cell surface, cell infection efficiency varies across tissues, indicating organ targeting specificity. AAV8 is frequently used in liver research and is therefore the serotype of choice for generation of the AAV-HBV mouse model.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The use of this product for AAV-HBV mouse model preparation can greatly reduce the lead time for in vivo hepatitis B infection treatment development and help us accelerate the development of hepatitis B drug research and treatment programs, and is recommended.
This product has the advantages of high titer and low vacancy rate, which is very suitable for the construction of HBV-infected mouse models.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
